Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies
International journal of radiation oncology, biology, physics（2017）
摘要
We present early toxicity and efficacy findings from a phase 2 trial that combines CTLA4 blockade (ipilimumab) with stereotactic ablative radiation therapy (SABR) targeting metastatic lung or liver lesions in patients with solid tumors.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要